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Abstract
Background
Orofacial clefts are congenital malformations of the orofacial region, with a glo-
bal incidence of one per 700 live births. Interferon Regulatory Factor 6 (IRF6)
(OMIM:607199) gene has been associated with the etiology of both syndromic
and nonsyndromic orofacial clefts. The aim of this study was to show evidence
of potentially pathogenic variants in IRF6 in orofacial clefts cohorts from Africa.
Methods
We carried out Sanger Sequencing on DNA from 184 patients with nonsyn-
dromic orofacial clefts and 80 individuals with multiple congenital anomalies that
presented with orofacial clefts. We sequenced all the nine exons of IRF6 as well as
the 50 and 30 untranslated regions. In our analyses pipeline, we used various
bioinformatics tools to detect and describe the potentially etiologic variants.
Results
We observed that potentially etiologic exonic and splice site variants were non-
randomly distributed among the nine exons of IRF6, with 92% of these variants
occurring in exons 4 and 7. Novel variants were also observed in both nonsyndromic
orofacial clefts (p.Glu69Lys, p.Asn185Thr, c.175-2A>C and c.1060+26C>T) and
multiple congenital anomalies (p.Gly65Val, p.Lys320Asn and c.379+1G>T) patients.
Our data also show evidence of compound heterozygotes that may modify pheno-
types that emanate from IRF6 variants.
Conclusions
This study demonstrates that exons 4 and 7 of IRF6 are mutational ‘hotspots’
in our cohort and that IRF6 mutants-induced orofacial clefts may be prevalent
in the Africa population, however, with variable penetrance and expressivity.
These observations are relevant for detection of high-risk families as well as
genetic counseling. In conclusion, we have shown that there may be a need to
combine both molecular and clinical evidence in the grouping of orofacial clefts
into syndromic and nonsyndromic forms.
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Introduction
Orofacial clefts (OFCs) are congenital craniofacial abnor-
malities with a global prevalence of one per 700 live
births (Mossey and Modell 2012). OFCs may be syn-
dromic or nonsyndromic, with the syndromic forms pre-
senting with other congenital malformations such as lip
pits, heart defects, hexadactyly, etc. Nonsyndromic OFCs
(NSOFCs) may present as nonsyndromic cleft lip only
(NSCL), nonsyndromic cleft lip and palate (NSCLP) and
nonsyndromic cleft palate only, NSCPO (Dixon et al.
2011). In the Online Mendelian Inheritance in Man data-
base (OMIM), over 300 different syndromes present with
clefts (www.omim.org). Van der Woude Syndrome
(VWS, OMIM:119300) and Popliteal Pterygium Syn-
drome (PPS, OMIM:119500) are allelic syndromes that
are characterized by clefts and other anomalies. These
syndromes emanate mainly from etiologic variants in
IRF6 (OMIM:607199) gene (Kondo et al. 2002), though
GRHL3 (OMIM:608317) (Peyrard-Janvid et al. 2014) has
been shown to be mutated in about 5% of VWS patients
that lack etiologic variants in IRF6. VWS is the most
common syndromic form of cleft, accounting for about
2% of all clefts and increases the recurrence risk about
threefold (Ghassibe et al. 2004). Nonpathogenic common
variants (Zucchero et al. 2004) and functionally validated
single-nucleotide polymorphism (SNP) in AP-2a enhancer
element (Rahimov et al. 2008) in and near IRF6 have also
been associated with nonsyndromic cleft lip with or with-
out palate (NSCL/P).
Inasmuch as over 300 etiologic variants in IRF6 have
been reported worldwide in patients with VWS and PPS,
these variants are nonrandomly distributed among the
seven coding exons of the gene (Kondo et al. 2002; Fer-
reira de Lima et al. 2009; Leslie et al. 2013; Butali et al.
2014a). These variants are usually concentrated in the
highly conserved DNA-binding domain (exons 3 and 4)
and less conserved transactivation domain (exons 7 and
9) (Ferreira de Lima et al. 2009). Recent sequence analy-
ses of these four exons in VWS and PPS patients from
Africa confirmed that these four exons are mutational
“hot-spots” in IRF6 (Butali et al. 2014a). The study, how-
ever, involved only two African populations, Ethiopia and
Nigeria. This study mainly sought to detect etiologic IRF6
variants in both NSOFC and multiple congenital anoma-
lies (MCA) patients from Ghana, an unstudied popula-
tion. We also directly sequenced PAX7 (OMIM: 167410)
in our NSOFC Ghanaian cohort. Moreover, MCA patients
from Ethiopia and Nigeria were also included in the
genetic analyses that involved direct DNA sequence analy-
ses of all the 9 exons of IRF6. MCA patients were
screened for IRF6 pathogenic variants for two reasons.
Firstly, to detect etiologic variants in classical VWS
patients as well as patients with spectrum of phenotypes
that have been reported in PPS patients. Secondly, all syn-
dromes were included in the MCA cohort so as to ascer-
tain whether IRF6 etiologic variants modify the
phenotypes of these syndromes.
Materials and Methods
Ethical compliance
All sample and data collection at various study sites were
approved by the local Institutional Review Boards: College
of Health Sciences, Kwame Nkrumah University of
Science and Technology (KNUST), Ghana – CHRPE/AP/
217/13, College of Medicine, University of Lagos, Nigeria
– ADM/DCST/HREC/APP/1374 and College of Health
Sciences, Addis Ababa University, Ethiopia - 3.10/027/
2015. Before sample collection, written informed consent
was obtained from all participants.
Subjects
We selected 184 NSOFC (60 NSCL, 71 NSCLP and 53
NSCPO) and 54 MCA patients from indigenous Ghanaian
patients with OFC that were encountered by the Cleft-
Craniofacial Team of Komfo Anokye Teaching Hospital
(KATH), Kumasi, Ghana. Moreover, to increase the sam-
ple size for MCA patients, we added six and 20 MCA
patients from Ethiopia and Nigeria, respectively, to the
study cohort. The Ethiopian patients were recruited from
Yekatit 12 Hospital, Addis Ababa, whereas the Nigerian
patients were recruited from University of Lagos Teaching
Hospital and Obafemi Awolowo University Teaching
Hospital. In all, 80 MCA patients formed the study
cohort.
At the time of sample collection and clinical examina-
tion, none of the NSOFC patients showed any other clini-
cal abnormalities in addition to the OFCs. All OFC
patients that presented with any congenital deformity in
addition to OFC were classified as having MCAs. These
patients included those with known syndromes like VWS,
Pierre Robin Sequence (PRS), Apert Syndrome, Kabuki
Syndrome, Moebius Syndrome, Stickler’s syndrome, etc.
Other patients with OFC also presented with club foot
only, hexadactyly, heart defects, microphthalmia, anoph-
thalmia, hypospadias, ankyloglossia, imperforate anus, etc.
(Fig. 1; Table S1).
DNA processing, PCR and electrophoresis
Saliva or cheek swab samples were collected from all par-
ticipants, using the Oragene DNA Collection Kits (http://
www.dnagenotek.com). We extracted DNA from all
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samples using the Oragene Saliva processing protocol. We
then quantified the DNA, using Quibit Assay that
employed Quibit 2.0 Fluorometer (http://www.invitroge
n.com/site/us/en/home/brands/Product-Brand/Qubit.html),
followed by XY-Genotyping to validate the sexes of the
samples. Primer sequences that were used to amplify
exons 1 to 9 of IRF6 (RefSeq NM_006147.3) and PAX7
(RefSeq NM_001135254.1) have been published else-
where (Ferreira de Lima et al. 2009; Butali et al. 2014a,
b). All DNA processing protocols, PCR conditions and
electrophoretic procedure are available at the Murray
laboratory website (http://genetics.uiowa.edu/protocols.
php).
Analyses of DNA sequence results
Amplified DNA products were sequenced at Functional
Biosciences in Madison, Wisconsin (http://order.functiona
lbio.com/seq/index), using an ABI 3730XL DNA Seq-
uencer (http://www.appliedbiosystems.com/absite/us/en/
home.html) that employed Sanger Sequencing Technol-
ogy. Chromatograms were then transferred to a Unix
workstation, base-called with PHRED (http://www.phrap.
org/phredphrapconsed.html, v.0.961028), assembled with
PHRAP (http://www.phrap.org/, v.0.960731), scanned by
POLYPHRED (http://droog.gs.washington.edu/polyphred/,
v. 0.970312) and viewed with CONSED programme
(http://www.phrap.org/consed/consed.html, v. 4.0).
The genomic location of each variant revealed by
CONSED was ascertained using the “Blat” function of
UCSC Genome Browser (https://genome.ucsc.edu/). The
functional effect of a coding variant on protein was pre-
dicted, using Polyphen-2 (http://genetics.bwh.harvard.ed
u/pph2/) and Sift (http://sift.jcvi.org/). Simulation of
mutant protein structure was carried out using HOPE
(http://www.cmbi.ru.nl/hope). Effect of a variant on
mRNA splicing was ascertained using Human Splicing
Finder 3.0 (http://www.umd.be/HSF3/). Furthermore,
effect of a variant on a regulatory region was predicted,
using RegulomeDB (http://regulomedb.org/).
The Minor Allele Frequencies or novelty of a variant
was ascertained by comparing it to variants in 1000
Genomes (http://browser.1000genomes.org/index.html),
Exome Variant Server (http://evs.gs.washington.edu/EVS/
), dbSNP (www.ncbi.nlm.nih.gov/SNP/) and ExAC Brow-
ser (http://exac.broadinstitute.org/). Variants were classi-
fied as “novel” if they have never been reported in any of
these databases or literature. Upon detection of a variant
of interest in proband, samples from other relatives as
well as those of the probands, were then sequenced in the
reverse direction to confirm the variant and also to ascer-
tain whether a variant was de novo or segregated in a par-
ticular family. All novel coding variants have been
deposited in a cleft lip and palate mutation database
called LOVD (http://www.icp.ucl.ac.be/vikkula/CLPdb).
The accession numbers are: c.194G>T, IRF6_00051;
c.205G>A, IRF6_00052; c.554A>C, IRF6_00053 and
c.960G>C, IRF6_00054.
Results
After the various analyses pipelines stipulated in the
methodology, we observed 14 different rare and poten-
tially pathogenic variants in IRF6 in both syndromic and
nonsyndromic cleft patients (Table 1, Fig. 2). Seven of
these variants were novel. In silico analyses were based on
Ensemble transcript number ENST00000367021 for IRF6.
It must be noted that p.Asn185Thr was observed in an
individual with p.Glu69Lys variant. Apart from this, all
variants stated in the table were observed in different
individuals.
A VWS patient with bilateral CLP and lip pits had the
p.Gly65Val variant; the variant was not in the mother but
there was no sample from the father. The novel
p.Glu69Lys variant occurred in two NSOFC Ghanaian
patients: one with NSCPO and the other with right
NSCLP with bifid uvula. This variant segregated in a
pedigree, where the variant occurred in both the proband
and father, though the father had no overt cleft. In
another pedigree, the variant occurred in the proband,
but not the only maternal sample available. Both clinically
unaffected father and an NSCLP patient had the p.Asn88-
Ser variant. The p.Arg250Gln was observed in a VWS
patient with bilateral lip pits and alveolar cleft only;
Figure 1. A patient with Van der Woude Syndrome that presented
with CLP and bilateral lip pits (indicated by arrow heads).
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however, no parental samples were available to determine
whether this variant was de novo or segregated in the
family. The p.Lys320Asn was observed in a VWS patient
with bilateral CLP, bilateral lip pits and hypodontia; no
parental samples were available. The splice acceptor site
variant, c.175-2A>C, was observed in NSOFC patient with
left unilateral NSCLP, whereas the splice donor site vari-
ant, c.379 + 1 G>T, was found in a VWS patient with
bilateral CLP and bilateral lip pits. These two variants are
novel; however, some parental samples were not available
for us to determine whether they were segregating or de
novo.
According to HOPE (http://www.cmbi.ru.nl/hope),
three of the novel mutations affected the structure and
function of IRF6 protein for a number of biochemical
reasons. Both the p.Glu69Lys and p.Gly65Val variants
occurred in the highly conserved, N-terminal helix-turn-
helix DNA-binding domain, whereas p.Lys320Asn
occurred in the transactivation domain. For p.Glu69Lys,
glutamate is relatively smaller and negatively charged
whereas Lysine is relatively larger and positively-charged
(Fig. 3). The mutant valine residue in p.Gly65Val is larger
and has relatively higher hydrophobicity than glycine
(Fig. 4). For p.Lys320Asn variant, asparagine is relatively
smaller and neutral in charge, whereas lysine is relatively
larger and positively charged (Fig. 5).
Discussion
We observed that etiologic variants in IRF6 were nonran-
domly distributed among the seven coding exons of the
gene; we also could not detect IRF6 etiologic variants in
all VWS patients. All etiologic coding and splice site vari-
ants (12 out of 13 variants, about 92%), except
p.Asn185Thr in exon 6, were distributed between exons 4
and 7 of the gene, confirming earlier observations (Kondo
et al. 2002; Ferreira de Lima et al. 2009; Butali et al.
2014a). This observation is relevant for genetic testing in
Africa: with limited resources, one can focus on exons 4
and 7 when the need arises to sequence the DNA of a
subject. Moreover, we detected potentially etiologic IRF6
variants in nine out of the 13 (about 69%) patients with
VWS. The lack of etiologic IRF6 variants in all VWS
patients buttresses the point that other upstream or
downstream IRF6 target genes or genes in the same regu-
latory network as IRF6 may also contribute to clefting in
VWS and PPS patients, as etiologic IRF6 variants are
observed in only about 70% of VWS patients (Rorick
et al. 2011; Wu-Chou et al. 2013; Fakhouri et al. 2014;
Peyrard-Janvid et al. 2014; Kwa et al. 2015). Our analyses
also showed that 18 out of the 184 patients with NSOFCs
had potentially etiologic IRF6 variants, suggesting etio-
logic IRF6 variants occurred in about 9% of our study
Table 1. Rare and potentially pathogenic variants observed in IRF6.
HGVS HGVp a b Polyphen-2 Sift Human splice finder RDB Reference
achr1:209,979,529 A>T (rs34743335) N/A 5 1 N/A N/A N/A i 29
c.175-2A>C N/A 1 0 N/A N/A c N/A Novel
c.194G>T p.Gly65Val 0 1 Probably Damaging Deleterious N/A N/A Novel
c.205G>A p.Glu69Lys 2 0 Probably Damaging Deleterious N/A N/A Novel
c.263A>G p.Asn88Ser 1 0 Probably Damaging Deleterious N/A N/A 14
c.334C>G p.Gln112Glu 2 0 Benign Tolerated N/A N/A 29
c.379+1G>T N/A 0 1 N/A N/A d N/A Novel
c.380-116T>A N/A 5 2 N/A N/A e, f, g N/A 29
c.554A>C p.Asn185Thr 1 0 Benign Tolerated h N/A Novel
c.749G>A p.Arg250Gln 0 1 Probably Damaging Deleterious N/A N/A 14
c.748C>T p.Arg250X 1 2 N/A N/A N/A N/A 14
c.945G>A p.Arg315Arg 1 0 Benign Tolerated h N/A 30
c.960G>C p.Lys320Asn 0 1 Probably Damaging Deleterious N/A N/A Novel
c.1060+26C>T N/A 1 0 N/A N/A N/A i Novel
a: Total number observed in NSCL/P patients, b: Total number observed in syndromic clefts, c: Alteration of the wild-type acceptor site – most
probably affecting splicing, d: Alteration of the wild-type donor site – most probably affecting splicing, e: Activation of an intronic cryptic acceptor
site, f: Activation of an intronic cryptic donor site, g: creation of an intronic ESE site, h: Alteration of an exonic ESE site; potential alteration of
splicing, i: 2b-Likely to affect binding of POLR2A. RDB: RegulomeDB software, a: no HGVS available for this variant. Transcript variant 1 of IRF6
(RefSeq NM_006147.3) based on human genome assembly GRCh37/hg19 of 2009 was sequenced. All novel coding variants have been deposited
in a cleft lip and palate mutation database called LOVD (http://www.icp.ucl.ac.be/vikkula/CLPdb). The accession numbers are: c.194G>T,
IRF6_00051; c.205G>A, IRF6_00052; c.554A>C, IRF6_00053 and c.960G>C, IRF6_00054. 14Ferreira de Lima RLL, Hoper SA, Ghassibe M et al.
Prevalence and nonrandom distribution of exonic mutations in Interferon Regulatory Factor 6 (IRF6) in 307 families with Van der Woude syndrome
and 37 families with popliteal pterygium syndrome. Genet Med. 2009: 11(4): 241–247; 29www.ncbi.nlm.nih.gov/SNP/; 30http://exac.broadinsti
tute.org/.
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cohort. These 18 variants included both coding and splice
site variants (a total of 12), as well as potentially etiologic
regulatory region (enhancer) variants (a total of six).
Furthermore, no etiologic IRF6 variants were observed in
other MCAs, save VWS patients. Interestingly, some of
these MCA patients had phenotypes that have been
reported in PPS patients (Ghassibe et al. 2004; Sarode
et al. 2011]. These included hexadactyly, syndactyly,
undescended testes, hypospadias, nail and toe aplasia,
club foot, microphthalmia, etc. This observation suggests
other known or unknown syndromes may account for
Figure 2. DNA Sequence chromatograms and pedigrees for p.Glu69Lys variant. (A): top chromatogram is from an unaffected individual, whereas
the middle and bottom chromatograms are from two patients with p.Glu69Lys variant, (B): a case with IRF6 (RefSeq NM_006147.3) compound
heterozygote, (C): a case with IRF6-PAX7 (RefSeq NM_001135254.1) compound heterozygote.
Figure 3. Substitution of Glutamate for Lysine in p.Glu69Lys mutant
in IRF6 (RefSeq NM_006147.3).
Figure 4. Wildtype and mutant amino acid residues for p.Gly65Val
variant in IRF6 (RefSeq NM_006147.3).
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these extracongenital anomalies, since over 300 syndromes
present with cleft and other birth defects (OMIM).
We also observed that potentially etiologic variants in
IRF6 exhibited variable penetrance in that the lip pits that
are usually associated with VWS were absent in the
NSOFCs patients; some of these variants were also
observed in both patients with overt cleft and clinically
unaffected parents. Based on molecular evidence, the two
patients with p.Glu69Lys variant are actually VWS
patients, instead of NSOFC patients. However, during
clinical assessment, the classical VWS phenotype that
occurs with CL/P, lip pits, were absent. This suggests that
though these a priori NSOFC patients are actually VWS
patients, the lip pit phenotype was not penetrant, but-
tressing earlier observations on lack of lip pits or lip pit
variability in individuals carrying etiologic variants in
IRF6 (Desmyter et al. 2010; Rutledge et al. 2010). The
two patients that had the p.Glu69Lys variant had other
variants that could have modified their phenotype: the
NSCPO patient also had p.Pro408Leu variant in PAX7
(OMIM:167410) whereas the NSCLP also had another
mutation (p.Asn185Thr) in IRF6. Interactions between
IRF6 and other genes have been suggested by a study
(Leslie et al. 2013). Therefore, compound heterozygosity
and epistasis (gene-gene interactions) may explain why
phenotypes of IRF6 etiologic variants are variable and
why parents carrying single variants of either IRF6 or
PAX7 had no overt cleft. It is also possible that parents
who harbored potentially etiologic variant in IRF6 or
PAX7 may also have subclinical phenotypes that have
been associated with OFCs. These possibilities require fur-
ther investigation in future studies. Thus, our study and
other studies (Marazita et al. 2009; Dixon et al. 2011)
presuppose the need to carry out deep subclinical pheno-
typing in families with history of clefts. This is warranted
by the fact that some individuals without overt OFCs but
that have certain subclinical phenotypes (such as orbicu-
laris oris muscle defects, ankyloglossia, atypical lip pits or
bumps, alterations in brain structure, facial asymmetry,
velopharyngeal insufficiency, dental anomalies, congenital
absence of uvula, etc.) have been shown to harbour etio-
logic IRF6 variants (Nopoulos et al. 2007; Vieira et al.
2008; Neiswanger et al. 2009; Weinberg et al. 2009; Yee-
tong et al. 2009; Dixon et al. 2011).
Finally, we observed that patients carrying the same
potentially etiologic variants in IRF6 exhibited variable
expressivity. The protein-truncating variant p.Arg250X
was observed in both nonsyndromic and VWS patients:
the NSCL case had no lip pits whereas the VWS patients
had lip pits. The two VWS patients with the p.Arg250X
variant have variable phenotypes: a patient had bilateral
CLP, ankyloglossia and bilateral lip pits whereas the other
patient had right unilateral CL and bilateral lip pits.
However, we could not get samples from all parents to
determine whether this variant was de novo or segregated
in these families. Variable VWS and PPS phenotypes
which are usually caused by a single etiologic variant have
been observed both within and between families (Ghas-
sibe et al. 2004; de Medeiros et al. 2008; Ferreira de Lima
et al. 2009; Birkeland et al. 2011; Malik et al. 2014). To
make our observations very clinically relevant, future
studies may aim at sequencing IRF6 gene in larger cohort
from Africa.
Conclusion
We have shown for the first time in the Ghanaian popu-
lation the evidence of novel etiologic IRF6 variants in
most patients with VWS as well as some NSOFC patients.
In support of an earlier study, our study has shown that
IRF6 etiologic variants may be prevalent in the African
population, however, with variable penetrance and
expressivity. To the best of our knowledge, we have also
shown for the first time an evidence of IRF6-IRF6 and
IRF6-PAX7 compound heterozygotes that may modify
phenotypes that emanate from IRF6 etiologic variants.
These observations are relevant for detection of high-risk
families, genetic counseling as well as future sequencing
projects that may initially limits sequencing to exons 4
and 7 of IRF6. In conclusion, our study suggests there
may be the need to combine both molecular and clinical
evidence in the classification of OFCs into syndromic and
nonsyndromic forms.
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